Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
NCT07089303, Recruiting, Chinese PLA General Hospital
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER) | ClinicalTrials.gov |
| NCT number | NCT07089303 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 750 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chinese PLA General Hospital | ClinicalTrials.gov |
| Conditions | Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | ClinicalTrials.gov |
| First posted | 2025-07-28 | ClinicalTrials.gov |
| Last updated | 2025-08-14 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Regional Brain Sodium Concentration (mmol/L) Measured by 7 T ²³Na-MRI | Baseline to 1 year | Quantitative regional brain sodium concentration measured by 7 T sodium (²³Na) MRI; units mmol/L; higher values indicate increased sodium concentration. | ClinicalTrials.gov |
| Primary | Change from Baseline in Resting-State Fractional Amplitude of Low-Frequency Fluctuations（fALFF, unitless) Measured by 7 T fMRI | baseline to 1year | Fractional Amplitude of fALFF averaged within gray-matter mask (unitless; higher = greater spontaneous activity). | ClinicalTrials.gov |
| Primary | Change from Baseline in Mean Apparent Diffusion Coefficient (ADC) (×10-³ mm²/s) Derived from Dynamic Diffusion-Weighted Imaging (DynDWI) | Baseline to 1 year | Mean ADC (×10-³ mm²/s) derived from DynDWI; higher values indicate increased diffusivity. | ClinicalTrials.gov |
| Primary | Change From Baseline in Fractional Anisotropy (FA, unitless) | Baseline to 1 year | Change from baseline in DTI-derived FA values in major white matter tracts; higher FA indicates greater microstructural integrity. | ClinicalTrials.gov |
| Primary | Change From Baseline in Mean Diffusivity (MD, ×10-³ mm²/s) | Baseline to 1 year | Change from baseline in DTI-derived MD values in major white-matter tracts; higher MD indicates increased water diffusivity (×10-³ mm²/s). | ClinicalTrials.gov |
| Secondary | Change from Baseline in Montreal Cognitive Assessment (MoCA) Total Score (0-30, points) | Baseline to 1 year | Higher scores indicate better global cognition. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Clinical Dementia Rating (CDR) Global Score (0-3, points) | Baseline to 1 year | Higher scores indicate more severe dementia. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Mini-Mental State Examination (MMSE) Total Score (0-30, points) | Baseline to 1 year | Lower scores indicate greater impairment. | ClinicalTrials.gov |
| Secondary | Change From Baseline of the Auditory Verbal Learning Test (AVLT) Total Learning Score | baseline to 1year | AVLT total learning score is the sum of Trials N1-N6 (each trial scored 0-15; total range 0-90); higher scores indicate better verbal memory. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Rey-Osterrieth Complex Figure Test (ROCF) Combined Recall Score (0-72, points) | baseline to 1year | Combined Recall = Immediate Recall (0-36) + Delayed Recall (0-36), scored with the 36-point Osterrieth method; range 0-72. Higher scores indicate better visuospatial (visual) memory. | ClinicalTrials.gov |
| Secondary | Change From Baseline of the Clock Drawing Test (CDT) Score (0-5, points) | Baseline to 1 year | CDT score ranges 0-5; higher scores indicate better visuospatial and executive function. | ClinicalTrials.gov |
| Secondary | Change From Baseline of the Boston Naming Test (BNT) Total Score (0-60, points) | Baseline to 1 year | BNT total score ranges 0-60; higher scores indicate better confrontational naming ability. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Digit Span Test (DST) Total Score (0-15, points) | Baseline to 1 year | Forward (0-8) + backward (0-7); higher = better attention/working memory. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Symbol Digit Modalities Test (SDMT) Total Score (correct matches per 90 s) | Baseline to 1 year | SDMT total score is the number of correct symbol-digit matches in 90 seconds (typical range 0-110); higher scores indicate better processing speed and attention. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Stroop Color-Word Test (SCWT) Incongruent Condition Completion Time (seconds) | Baseline to 1 year | Shorter time indicates better cognitive flexibility and inhibition. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Neuropsychiatric Inventory (NPI) Total Score (0-144, points) | Baseline to 1 year | NPI total score ranges 0-144; higher scores indicate more severe neuropsychiatric symptoms. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Hamilton Anxiety Rating Scale (HAMA) Total Score (0-56, points) | Baseline to 1 year | HAMA total score ranges 0-56; higher scores indicate more severe anxiety symptoms. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Hamilton Depression Rating Scale (HAMD) Total Score (0-52, points) | Baseline to 1 year | HAMD total score ranges 0-52; higher scores indicate more severe depressive symptoms. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Symptom Checklist-90 (SCL-90) Total Score (90-450, points) | Baseline to 1 year | SCL-90 total score ranges 90-450; higher scores indicate greater overall psychological distress. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Activities of Daily Living (ADL) Scale Score (0-100, points) | Baseline to 1 year | ADL total score ranges 0-100; higher scores indicate greater independence in basic self-care tasks. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 9
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Clock Drawing Task | Secondary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)